Program
basmisanil
Also written as “RG1662”, “Basmisanil” and “RO5186582”.
Its studies are mostly in Down Syndrome · Schizophrenia · Stroke, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 120 open or running | phase 2since Dec 27, 2013 | Aug 18, 2011 | none ahead |
| Newleos Therapeutics | 11 open or running | phase 2since Sep 18, 2026 | Sep 18, 2026 | May 1, 2029phase 2 · NCT07846215 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 18, 2011First study: phase 1 study in Down SyndromeNew to Hoffmann-La RocheHoffmann-La Roche · NCT01436955 · 35 enrolled · United States, United Kingdom
- Aug 14, 2012Phase 1 study in Down SyndromeHoffmann-La Roche · NCT01667367 · 13 enrolled · United Kingdom
- Sep 11, 2012Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01684891 · 6 enrolled · Netherlands
- Dec 27, 2013Phase 2 study in Down SyndromeHoffmann-La Roche · NCT02024789 · 173 enrolled · United States, Argentina, Canada and more
- Jul 8, 2014Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT02194244 · 18 enrolled · United Kingdom
- Sep 23, 2014Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT02254759 · 12 enrolled · United Kingdom
- May 13, 2015Phase 1 study in Healthy Patient StudyHoffmann-La Roche · NCT02470832 · 12 enrolled · United Kingdom
- Jun 16, 2015Phase 2 study in Down SyndromeHoffmann-La Roche · NCT02484703 · 45 enrolled · United States
- Aug 21, 2015Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT02534207 · 6 enrolled · United Kingdom
- Oct 7, 2016Phase 2 study in StrokeHoffmann-La Roche · NCT02928393 · 5 enrolled · France, Spain
- Nov 1, 2016Phase 2 study in SchizophreniaHoffmann-La Roche · NCT02953639 · 214 enrolled · United States
- Mar 25, 2022Phase 2 study in Polyposis Syndrome, Hereditary Mixed, 1Hoffmann-La Roche · NCT05307679 · 7 enrolled · United States, Spain, United Kingdom
- Sep 18, 2026Newleos Therapeutics's first study: phase 2 study in Dup15Q SyndromeNew to Newleos TherapeuticsNewleos Therapeutics · NCT07846215 · 30 planned · United States
Ahead
- May 1, 2029Primary completion: phase 2 study in Dup15Q SyndromeNewleos Therapeutics · NCT07846215
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07846215Dup15Q Syndrome · United States | 2 | Not yet recruiting | Newleos Therapeutics | May 1, 2029 | 30 |
| NCT05307679Polyposis Syndrome, Hereditary Mixed, 1 · United States, Spain, United Kingdom | 2 | Terminated | Hoffmann-La Roche | Mar 4, 2024 | 7 |
| NCT02953639Schizophrenia · United States | 2 | Completed | Hoffmann-La Roche | Dec 12, 2019 | 214 |
| NCT02928393Stroke · France, Spain | 2 | Terminated | Hoffmann-La Roche | Nov 3, 2017 | 5 |
| NCT02534207Healthy Volunteer · United Kingdom | 1 | Completed | Hoffmann-La Roche | Oct 2015 | 6 |
| NCT02484703Down Syndrome · United States | 2 | Terminated | Hoffmann-La Roche | Aug 3, 2016 | 45 |
| NCT02470832Healthy Patient Study · United Kingdom | 1 | Completed | Hoffmann-La Roche | Jul 2015 | 12 |
| NCT02254759Healthy Volunteer · United Kingdom | 1 | Completed | Hoffmann-La Roche | Nov 2014 | 12 |
| NCT02194244Healthy Volunteer · United Kingdom | 1 | Completed | Hoffmann-La Roche | Aug 2014 | 18 |
| NCT02024789Down Syndrome · United States, Argentina, Canada and more | 2 | Completed | Hoffmann-La Roche | May 4, 2016 | 173 |
| NCT01684891Healthy Volunteer · Netherlands | 1 | Completed | Hoffmann-La Roche | Oct 2012 | 6 |
| NCT01667367Down Syndrome · United Kingdom | 1 | Completed | Hoffmann-La Roche | Oct 2013 | 13 |
| NCT01436955Down Syndrome · United States, United Kingdom | 1 | Completed | Hoffmann-La Roche | Sep 2013 | 35 |
How it is read
Names in the registry
- “RG1662”, 6 entries
- “Basmisanil”, 5 entries
- “RO5186582”, 2 entries
- “RG1662 granules”, 1 entry
Conditions, from the studies’ own filings
- Down Syndrome, 4 studies
- Schizophrenia, 1 study
- Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.